MGMT and neoplasm: For example, the AI-guided delineation of epigenetic corrections (e.g., MGMT enhancer re-silencing, CDKN2A reactivation, or reprogramming immunosuppressive tumor-associated macrophages through blockade of a C/EBPβ enhancer) may provide an in silico preview of whether these interventions will translate into the functional restoration of the pathways of interest or will suffer from significant off-target consequences [241].